Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. decreased its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 4.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,500,000 shares of the biotechnology company's stock after selling 350,000 shares during the period. Adage Capital Partners GP L.L.C. owned about 5.59% of Heron Therapeutics worth $13,005,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Barclays PLC raised its stake in Heron Therapeutics by 29.8% during the third quarter. Barclays PLC now owns 218,455 shares of the biotechnology company's stock worth $434,000 after acquiring an additional 50,109 shares during the period. Principal Financial Group Inc. raised its position in shares of Heron Therapeutics by 456.5% during the 3rd quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company's stock worth $204,000 after purchasing an additional 84,205 shares during the period. JPMorgan Chase & Co. raised its position in shares of Heron Therapeutics by 295.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock worth $411,000 after purchasing an additional 154,487 shares during the period. Congress Park Capital LLC lifted its holdings in shares of Heron Therapeutics by 24.1% in the 4th quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock worth $3,757,000 after purchasing an additional 477,417 shares during the last quarter. Finally, Arkadios Wealth Advisors acquired a new position in Heron Therapeutics during the 4th quarter valued at approximately $76,000. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Stock Down 1.7 %

Heron Therapeutics stock traded down $0.04 during mid-day trading on Friday, hitting $2.31. 1,458,539 shares of the company's stock traded hands, compared to its average volume of 2,306,930. Heron Therapeutics, Inc. has a one year low of $1.04 and a one year high of $3.93. The firm has a 50 day moving average price of $2.18 and a 200 day moving average price of $1.80. The company has a market cap of $351.88 million, a PE ratio of -12.83 and a beta of 1.39.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.05. The company had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. On average, analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $4.00 target price on shares of Heron Therapeutics in a research note on Friday, April 11th. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.